Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

PURPOSE Preoperative chemoradiotherapy according to the chemoradiotherapy for
esophageal cancer followed by surgery study (CROSS) has become a standard of care for …

Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

METHODS This guideline is based on the previous colon cancer parameter published in
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …

Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

INTRODUCTION The goal of earlier cancer detection is to identify the disease at a stage
when it can be effectively treated, thereby offering the patient a better chance of long-term …

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis,
pathologic staging, surgical management, perioperative treatment, surveillance …